Quintrio
Home

SERVICES-TESTING LABORATORIES

20/20 Biolabs, Inc. Common Stock

AIDX

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.184 – $0.193
Volume 150,408
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for AIDX.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AIDX, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026
Revenue$730.57K$353.38K
Cost of revenue$425.84K$290.49K
Gross profit$304.73K$62.88K
Selling, general and administrative$1.29M$1.35M
Research and development$257.63K$153.48K
Total operating expenses$1.55M$1.51M
Operating income-$1.24M-$1.44M
Interest expense-$272.25K-$267.01K
Income before taxes-$1.51M-$2.17M
Income taxes$0$0
Net income-$1.51M-$2.17M
Net income attributable to common shareholders-$2.75M-$2.12M
EBITDA-$1.24M-$1.43M
Basic earnings per share-$0.26-$0.28
Diluted earnings per share-$0.26-$0.28

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

20/20 BioLabs announced a rescheduled investor webinar for September 2, 2026 at 2:00 p.m. ET to discuss Q2 2026 results featuring record OneTest™ revenue of $0.7 million (47.1% YoY increase), gross margin expansion to 41.7%, and commercial expansion across multiple channels including firefighter cancer screening programs.

GlobeNewswire Inc.

20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month

20/20 BioLabs (Nasdaq: AIDX) announced the launch of a recurring monthly investor webinar series starting July 1, 2026, held on the first Wednesday of each month at 12:00 p.m. ET. The initiative aims to increase transparency, strengthen shareholder communication, and provide direct access to management regarding the company's AI-powered blood tests for early cancer detection and chronic disease prevention.

GlobeNewswire Inc.

20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress

20/20 BioLabs (Nasdaq: AIDX) reported FY 2025 revenue of $2.0 million, up 17% year-over-year, with gross profit increasing 68% and gross margin expanding 900 basis points to 29.6%. The company achieved a 33% improvement in net loss to $3.7 million and reduced operating expenses by 35%. Recent highlights include a $5.0 million funding round, Nasdaq listing, $520,000 in Maryland state funding for firefighter cancer screenings, and launch of OneTest for Longevity. Management expects 2026 to be a breakout year driven by strong demand across firefighting, veterans, and occupational health markets.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.